<Header>
<FileStats>
    <FileName>20241031_10-Q-A_edgar_data_1411057_0001683168-24-007497.txt</FileName>
    <GrossFileSize>50724</GrossFileSize>
    <NetFileSize>11068</NetFileSize>
    <NonText_DocumentType_Chars>0</NonText_DocumentType_Chars>
    <HTML_Chars>34122</HTML_Chars>
    <XBRL_Chars>0</XBRL_Chars>
    <XML_Chars>0</XML_Chars>
    <N_Exhibits>2</N_Exhibits>
</FileStats>
<SEC-Header>
0001683168-24-007497.hdr.sgml : 20241031
<ACCEPTANCE-DATETIME>20241031140534
ACCESSION NUMBER:		0001683168-24-007497
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240831
FILED AS OF DATE:		20241031
DATE AS OF CHANGE:		20241031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cannabis Bioscience International Holdings, Inc.
		CENTRAL INDEX KEY:			0001411057
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				844901229
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-146758
		FILM NUMBER:		241414536

	BUSINESS ADDRESS:	
		STREET 1:		6201 BONHOMME ROAD
		STREET 2:		SUITE 435S
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77036
		BUSINESS PHONE:		214-733-0868

	MAIL ADDRESS:	
		STREET 1:		6201 BONHOMME ROAD
		STREET 2:		SUITE 435S
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHINA INFRASTRUCTURE CONSTRUCTION Corp
		DATE OF NAME CHANGE:	20090916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FIDELITY AVIATION CORP
		DATE OF NAME CHANGE:	20070829

</SEC-Header>
</Header>

 0001683168-24-007497.txt : 20241031

10-Q/A
 1
 cannabis_10qa1-83124.htm
 AMENDMENT NO 1

Table of Contents 

 UNITED STATES 

 SECURITIES AND EXCHANGE COMMISSION 

 Washington, DC 20549 

FORM 10-Q/A 

 (Amendment No. 1) 

(Mark One) 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the quarterly period ended August 31, 2024 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the transition period from _______________
to _______________ 

Commission File Number: 333-267039 

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS,
INC. 

 (Exact name of Registrant as specified in its charter) 

Colorado 
 84-4901299 
 
 (State or other jurisdiction of incorporation or organization) 
 (IRS Employer Identification No.) 

6201 Bonhomme Road, Suite 435N, Houston, TX 
 77036 
 
 (Address of Principal Executive Office) 
 (ZIP Code) 

(214) 733-0868 

 (Registrant s telephone number, including
area code) 

Securities registered pursuant to Section 12(b)
of the Act: 

Title of each class 
 Trading Symbol(s) 
 Name of each exchange on which registered 
 
 N/A 
 N/A 
 N/A 

Indicate by check mark whether the Registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes 
No 

Indicate by check mark whether the Registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). 
Yes No 

Indicate by check mark whether the Registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, 
and emerging growth company in Rule 12b-2 of the Exchange Act. 

Large accelerated filer 
 Accelerated filer 

Non-accelerated filer 
 Smaller reporting company 

Emerging growth company 

If an emerging growth company, indicate by check
mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the Registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
Yes No 

Indicate the number of shares outstanding of each
of the issuer s classes of common stock, as of October 21, 2024: 10,556,749,347 shares of common stock. 

Explanatory Note 

This Amendment No. 1 to the Quarterly Report on
Form 10-Q of Cannabis Bioscience International Holdings, Inc. for the quarter ended August 31, 2024, originally filed on August 21, 2024
(the Original Filing ), is filed (i) to add on the cover page the date on which the number of the Registrant s outstanding
shares of common stock was determined and (ii) to correct immaterial errors in certain numbers shown in Management s Discussion
and Analysis of Financial Condition and Results of Operations under the captions Net Loss 
and Changes in Financial Condition and Results of Operations, because these numbers do
not reflect those presented in the financial statements, which are unchanged by this Amendment No. 1. 

Pursuant to Rule 12b-15 under the Securities
Exchange Act of 1934, as amended, this Form 10-Q/A contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 

This Amendment No. 1 should be read in conjunction
with the Original Filing. 

Except as described above, no other changes
have been made to the Original Filing, and this Form 10-Q/A does not modify, amend or update in any way any of the financial statements
contained in the Original Filing, which were reviewed by the Registrant s registered public accounting firm. This Form 10-Q/A does
not reflect events that may have occurred subsequent to the filing date of the Original Filing. 

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS,
INC. 

QUARTERLY REPORT ON FORM 10-Q 

for the Quarterly Period Ended August 31, 2024 

TABLE OF CONTENTS 

Page 

PART I - FINANCIAL INFORMATION 

Item 2. 
 Management s Discussion and Analysis of Financial Condition and Results of Operations 
 
 4 

PART II - OTHER INFORMATION 

Item 6. 
 Exhibits 
 
 5 

SIGNATURES 
 
 6 

3 

PART I FINANCIAL
INFORMATION 

Item 2. Management s
Discussion and Analysis of Financial Condition and Results of Operations. 

Net Loss 

Net loss for the quarter ended August 31,
2024, was 76,305, compared with a net loss of 181,789 for the quarter ended August 31, 2023, for the reasons set forth above in relation
to loss from operations ended August 31, 2024. If the Company had not incurred the non-cash expense of 100,000 described above, it would
have recorded net income of 26,305 for the quarter ended August 31, 2024. 

Changes in Financial Condition and Results
of Operations 

At August 31, 2024, the Company had a balance
of 969 in cash and cash equivalents and accounts receivable of 17,176, negative working capital of 833,355 and no commitments for
capital expenditures. At May 31, 2024, the Company had 755 in cash and cash equivalents and accounts receivable of 20,139, negative
working capital of 860,416 and no commitments for capital expenditures. The Company had a negative balance of cash and cash equivalents
of 579 on the date of this Report. 

4 

PART II OTHER INFORMATION 

Item 6. Exhibits. 

Exhibit 
 Number 
 
 Title 

31 
 
 Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer and Principal Accounting Officer 
 
 32 
 
 Section 1350 Certification of Principal Executive Officer and Principal Accounting Officer 

5 

SIGNATURES 

Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by
the undersigned thereunto duly authorized. 

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC. 

Date: October 31, 2024 
 By: 
 /s/ Dante Picazo 

Dante Picazo 
Principal Executive Officer and Principal Accounting Officer 

6 

<EX-31>
 2
 cannabis_ex3101.htm
 CERTIFICATION

Exhibit 31 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL ACCOUNTING OFFICER 

 PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)AS
ADOPTED PURSUANT TO 

 SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 

I, Dante Picazo, certify that: 

1. 
 I have reviewed this Form 10-Q/A of Cannabis Bioscience
 International Holdings, Inc. for the three months ended August 31, 2024; 

2. 
 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. 
 Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report; 

4. 
 The Registrant s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d- 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have: 

(a) 
 Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b) 
 Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 

(c) 
 Evaluated the effectiveness of the Registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

(d) 
 Disclosed in this report any change in the Registrant s internal control over financial reporting that occurred during the Registrant s most recent fiscal quarter (the Registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant s internal control over financial reporting; and 

5. 
 The Registrant s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer s auditors and the audit committee of the small business issuer s board of directors (or persons performing the equivalent functions): 

(a) 
 All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer s ability to record, process, summarize and report financial information; and 

(b) 
 Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer s internal control over financial reporting. 

Date: October 31, 2024 

/s/ Dante Picazo 

 Dante Picazo 

 Principal Executive Officer and Principal Accounting Officer 

</EX-31>

<EX-32>
 3
 cannabis_ex3200.htm
 CERTIFICATION

Exhibit 32 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL ACCOUNTING OFFICER 

 PURSUANT TO 18 USC SECTION 1350 

 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002 

I, Dante Picazo, do hereby certify, pursuant to
18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: 

1. 
 The Quarterly Report on Form 10-Q/A of the Company for the quarter ended August 31, 2024, as filed with the Securities and Exchange Commission (the Report ), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

2. 
 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

Dated: October 31, 2024 

/s/ Dante Picazo 

 Dante Picazo 

 Principal Executive Officer and Principal Accounting Officer 

</EX-32>

